In advanced cancer including glioblastoma, the TGF-β pathway acts as an oncogenic factor. Some tumors exhibit aberrantly high TGF-β activity and the mechanisms underlying this phenomenon are not well understood. We have observed that TGF-β can induce TGF-β2 generating an autocrine loop leading to aberrantly high levels of TGF-β2. We identified CREB1
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an autocrine loop that leads to the accumulation of TGF-β2 ending in a hyperactivation of the TGF-β signal.
We went on to discern the mechanisms underlying the TGF-β autocrine loop and we identified the cAMP response element-binding protein 1 (CREB1) as a critical mediator and a SMAD cofactor of the induction of TGF-β2 by TGF-β. CREB1 belongs to the CREB/ATF family of transcription factors and is activated by means of phosphorylation in its Ser133 residue by different kinases including AKT and RSK (19) (20) (21) (22) . CREB factors promote tumorigenesis in many cancers, including non-small-cell lung carcinoma (NSCLC), acute myeloid leukemia (AML), and glioma (19, (23) (24) (25) (26) (27) . Interestingly, the CREB/ATF family of transcription factors have been shown to regulate and cooperate with SMADs in the transcriptional regulation of multiple genes (28) (29) (30) (31) . 
Results

TGF-β1 and TGF-β2 are highly expressed in GBM and confer poor prognosis
First, we decided to address whether the high activity of the TGF-β pathway present in some GBM tumors was due to the overproduction of the TGF-β ligands. Through the analysis of public data bases (Oncomine and REMBRANDT) we analyzed the mRNA levels of the TGF-β ligands and we observed that the levels of TGF-β1 and TGF-β2 mRNA were higher in GBM than in normal brain tissue while TGF-β3 is expressed at similar levels in GBM and in normal brain (Fig. 1A) . Interestingly, high levels of TGF-β1 or TGF-β2 conferred poor prognosis in GBM patients and that was not the case for TGF-β3 (Fig. 1B) . Based on these results, we decided to discern the molecular mechanisms involved in the overproduction of TGF-β2 mRNA.
Since the TGF-β2 gene is not targeted for amplification in GBM (data not shown, TCGA), we quickly discarded the possibility that TGF-β2 mRNA overproduction was due to an increase in gene dosage and decided to focus on the transcriptional regulation of TGF-β2. We observed that TGF-β2 mRNA was induced by TGF-β1 in a GBM cell line (LN299), while TGF-β1 and TGF-β3 mRNA levels were not affected by TGF-β1 treatment ( Fig. 2A) . Moreover, the effect of TGF-β on TGF-β2 was not specific of the ligand since TGF-β1, TGF-β2 and TGF-β3 induced the expression of TGF-β2 (Fig. 2B) . As expected the induction of the mRNA levels implied an induction of TGF-β2 protein secretion as observed through ELISA (Fig. 2C ). In addition, the induction of TGF-β2 by TGF-β was blunted by the treatment with the TβRI inhibitor, LY-2109761 (Fig. 2D ). This indicated that in LN299 cells an autocrine loop was generated where any TGF-β ligand induced TGF-β2 secretion and in turn TGF-β2 could induce its own expression. We decided to evaluate whether this phenomenon was unique for LN299 cells and we analyzed several cell lines (including GBM and non-GBM cell lines) for the presence of the TGF-β2 loop. We observed that TGF-β1 did not induce TGF-β2 in all GBM cell lines tested (i.e. A172), and on the other hand, the TGF-β2 loop was also present in some non-GBM cell lines, such as HACAT, MCF-7, SUM-159 and MDA-MB-231 (Fig. 2E) .
CREB1 regulates the induction of TGF-β2 by TGF-β
We went on to discern the molecular mechanisms involved in the regulation of TGF-β2 by TGF-β and we decided to study the TGF-β2 gene promoter region since our previous data showed that the regulation was at the transcriptional level. Looking for conserved regions among different animal species through sequence alignment, we found two conserved SMAD binding elements surrounding a cAMP response element (CRE) described to support CREB1 binding (Fig. 3A) .
CREB1 has been shown to interact and cooperate with SMADs in the transcriptional activation of certain genes (30, 31) . This suggested that CREB1 cooperates with SMADs to activate the TGF-β2 gene transcription. In order to assess this hypothesis, we performed RNA interference experiments using independently designed shRNAs and siRNAs targeting CREB1. Knock-down of CREB1 decreased the induction of TGF-β2 by TGF-β indicating that CREB1 is necessary for the regulation of the TGF-β2 transcription by TGF-β (Fig. 3B,C) . To further validate this result, we decided to develop an alternative experimental approach using an endogenous repressor of CREB1 called ICER (32) . Overexpression of ICER impaired the ability of TGF-β to induce TGF-β2 (Fig. 3D) . These results indicated that CREB1 is required for the TGF-β autocrine loop.
In order to prove that CREB1 binds to the identified CRE in the proximal region of the TGF-β2 promoter, we performed chromatin immunoprecipitation (ChIP) experiments. p-CREB1 and SMAD2 and/or SMAD3 bound to the proximal region of the TGF-β2 promoter and the interaction was increased in response to TGF-β (Fig. 4A) . Moreover, we performed reporter assays using a reporter construct containing the proximal -77/+64 region of the TGF-β2 promoter upstream of the luciferase gene. A reporter with a mutation in the CRE binding site was also engineered. TGF-β mildly but consistently induced the TGF-β2 reporter. However, TGF-β was not able to induce the transcriptional activity of the mutated version of the TGF-β2 reporter (Fig. 4B) . We decided to immunoprecipitate endogenous p-CREB1 and, interestingly, found that endogenous SMAD3 but not SMAD2 interacted with p-CREB1 in response to TGF-β (Fig. 4C ). To further assess the role of SMAD2 and SMAD3 in the process, we independently knocked down SMAD2 and SMAD3 using RNA interference. Knockdown of SMAD2 did not affect the induction of TGF-β2 by TGF-β while knockdown of SMAD3 repressed the TGF-β2 autocrine loop (Fig. 4D) . Together, our results showed that p-CREB1 formed a complex with SMAD3 to bind the CRE and the SBEs at the proximal region of the TGF-β2 promoter and induced the transcriptional activation of the promoter.
PI3K and RSK regulate the TGF-β2 autocrine loop through CREB1
CREB1 transcriptional activity is dependent on CREB1 phosphorylation at Ser133 by many different serine/threonine protein kinases including AKT and p90 ribosomal S6 kinase (RSK) (19) (20) (21) (22) . Phosphorylation at Ser133 is required for CREB1 binding to the transcriptional coactivator CREB1-binding protein (CBP) enabling the CREB1-dependent activation of transcription (33, 34) . We reasoned that if CREB1 transcriptional activity is required for the TGF-β2 autocrine loop, the signaling pathways that regulate CREB1 activity should also impact on the induction of TGF-β2 by TGF-β. To validate this hypothesis, we performed a and RSK (BI-D1870). As expected, CREB1 phosphorylation was reduced upon treatment with the PI3K inhibitor and the RSK inhibitor indicating that CREB1 activity was regulated by the PI3K-AKT and the RSK pathways (Fig. 5A, B) . In cells treated with the PI3K or RSK inhibitors, TGF-β was not able to induce TGF-β2 mRNA at the same level as in control cells (Fig. 5A, B) .
Moreover, both PI3K or RSK inhibitors impaired TGF-β2 protein secretion induced by TGF-β as measured by ELISA (Fig. 5C, D) . Interestingly, the effect of the inhibitor was more pronounced on the secretion of TGF-β2 than on the mRNA level of TGF-β2 possibly indicating a putative regulation of the TGF-β loop at the level of protein translation. Further work is required to validate this hypothesis.
TGF-β2 expression correlates with CREB1 protein levels in patient tumors
We then hypothesized that if CREB1 is required for the TGF-β2 autocrine loop, tumors with high levels of TGF-β2 might present elevated levels of CREB1 and p-CREB1. Through the analysis of the REMBRANDT database, we observed a positive correlation between TGF-β2 and CREB1 mRNA levels in human GBM samples (Fig. 6A) . Interestingly, there were no tumors with high TGF-β2 and low CREB1 (see the upper left quadrant of Fig. 6A ) showing the relevance of the CREB1 transcription factor on the expression of TGF-β2. The same analysis was performed in the case of TGF-β1 and no correlation was observed between TGF-β1 and CREB1 levels (Fig. 6B) . We went on to address whether TGF-β2 protein levels correlated with the levels of phosphorylated CREB1 performing an immunohistochemistry analysis of a collection of GBM samples. As expected, a positive correlation between TGF-β2 and p-CREB1 staining was observed (Fig. 6C ). Examples of a high and a low TGF-β2, p-CREB1 expressing tumors are shown. Interestingly, using the same collection of samples, we determined that p-CREB1 also correlated with p-SMAD2 levels ( Supplementary Fig. 1 ). Using again the REMBRANDT database, we observed that the patient population with tumors expressing high TGF-β2 and CREB1 had a significantly shorter overall survival than the rest of the patients indicating that combined upregulation of p-CREB1 and TGF-β2 confers poor prognosis in GBM patients (Fig. 6D ).
CREB1 regulates the levels of TGF-β2 in patient-derived xenograft models
We then decided to address the relevance of the CREB1-dependent TGF-β2 autocrine loop in patients. To this end, we used a patient-derived xenograft (PDX) model based on the orthotopic inoculation using stereotaxis of freshly obtained patient-derived tumor cells in the brain of immunocompromised mice (Fig. 7A ). The tumors generated in mice reproduce the same histopathological characteristics and oncogenic mutations as the tumor of the patient (4). We identified two patients that showed elevated expression levels of CREB1 and TGF-β2 in their tumors. Neurospheres from both patients were infected with lentivirus targeting CREB1 and cells were inoculated in mice. Tumors originated from the cells expressing the shRNA targeting CREB1, expressed lower levels of CREB1 and, importantly, lower levels of TGF-β2 ( overall survival of mice was longer than control mice (Fig. 7C ). This is in agreement with our previous work in which we showed that TGF-β regulates the ability of neurospheres to initiate tumors (3, 4) and, moreover, the two selected models respond to TGF-β receptor inhibitors (unpublished observations) indicating that in those two tumors the regulation of the TGF-β activity is relevant for cancer progression.
Research. 
Discussion
The oncogenic function of the TGF-β pathway is progressively being elucidated. In advanced tumors, TGF-β can induce proliferation, invasion, angiogenesis and immunesuppression (1, 2).
In addition, TGF-β can increase the self-renewal capacity of a cell population with stem-cell characteristics called the cancer-initiating cells (CICs) (3) (4) (5) . Due to its role in oncogenesis, TGF-β is considered a therapeutic target and several clinical trials using anti-TGF-β agents are nowadays under clinical development (6, 7). However, one of the crucial questions still remaining is how to predict in which tumors TGF-β acts as an oncogenic factor and thus which patients should be treated with anti-TGF-β compounds.
Work from our lab and others has shown that tumors present diverse levels of TGF-β activity. In particular in GBM, we observed that some tumors show aberrantly high TGF-β activity and this correlated with poor prognosis (16) . The presence of an extremely high TGF-β activity in the most aggressive tumors suggests that TGF-β may confer a selective advantage to the tumor and hence the inhibition of the TGF-β pathway might exhibit an anti-tumoral effect. But, why are there tumors with such a high TGF-β activity? Interestingly, the answer does not reside in the presence of activating genomic alterations of components of the TGF-β pathway as it happens in many other oncogenic pathways. In fact, in glioblastoma, the components of the TGF-β signal are seldom mutated and no gene amplifications of the TGF-β ligands nor hyperactive mutations in the TGF-β receptors have been described (1) .
In order to discern the molecular mechanisms underlying the increased TGF-β activity in GBM, we specifically focused on TGF-β2. We observed that TGF-β induced TGF-β2 and that in turn TGF-β2 induced its own expression. This generated a self-feeding autocrine loop leading to extremely high levels of TGF-β2. However, the autocrine loop was not present in all the cell lines tested and hence the TGF-β2 response to TGF-β depended on the cellular context. This is a typical characteristic of the TGF-β signaling pathway. The specific responses to TGF-β are determined by the characteristics of the cell that receives the signal. Frequently, the pleiotropic response to TGF-β is determined by the SMAD transcription complex. SMADs have low affinity for DNA and they cooperate with other transcription factors to bind to specific gene promoters. We corroborated our data analyzing human tumors. A correlation between CREB1 or p-CREB1 and TGF-β2 was observed and more importantly no tumor expressing low levels of CREB1 presented high TGF-β2. This was not the case for TGF-β1. Importantly, patients with tumors expressing high levels of CREB1 and TGF-β2 had a shorter overall survival than the rest of the patients. Moreover, CREB1 transcriptional activity is induced upon phosphorylation by many different protein kinases that in turn are regulated by oncogenic signaling pathways such as the PI3K-AKT and the RSK pathways (19, 21, 22) . This implies that in order to establish a TGF-β2 autocrine loop the tumor cell has to express CREB1 and, at the same time, exhibit an active PI3K or RSK pathways in order to acquire a high level of phosphorylated CREB1 (Fig. 7D) . In this might be considered a biomarker of response to anti-TGF-β treatments. Moreover, since CREB1 has been described as a putative therapeutic target (36, 37), our results suggest that compounds against CREB1 could be effective anti-cancer agents due to their effect on the oncogenic levels of TGF-β2.
Materials and methods
Plasmids
The CREB1 short hairpin sequence used was: 5'-GAGAGAGGTCCGTCTAATG-3' and the lentiviral knockdown sequences targeting CREB1 used were:
(1 
Antibodies and reagents
Specific antibodies against p-SMAD2, SMAD2, p-AKT, AKT, p-CREB1 and CREB1 (Cell Signaling); TGF-β2 and CREM (Santa Cruz Biotechnology); Tubulin (Sigma) were used for immunoblot and immunohistochemistry. Antibodies against SMAD2/3 (Upstate), ChIPAb+™
Phospho-CREB1 (Ser133) (Millipore) and rabbit IgG (Upstate) were used for ChIP and immunoprecipitation.
The treatments used were as follows: TGF-β1, TGF-β2, TGF-β3 (100 pM; R&D), PI3K inhibitor LY-294002 (10 μM; Merck Millipore), TβRI inhibitor LY-2109761 (Tocris); RSK inhibitor BI-D1870 (5 μM; Axon Medchem BV).
Cell culture
GBM neurospheres were generated as described previously (4, 39) . Briefly, tumor samples were processed within 30 minutes after surgical resection. Minced pieces of human GBM samples were digested with collagenase I (200 U/ml ;Sigma) and DNase I (500 U/ml ;Sigma) in PBS for 
RNA extraction, retrotranscription and Quantitative Real Time PCR
Cells were seeded in 60 mm plates at 70% confluency. After the described treatments, cultured cells were disrupted in lysis buffer from RNeasy Mini Kit (Qiagen) and mRNA was purified following manufacturer's instructions. mRNA was quantified and 300-800 ng of mRNA from each sample were retrotranscribed using the High Capacity cDNA Reverse Transcription Kit performed. All qRT-PCR were performed using Taqman probes from Applied Biosystems, according to the manufacturer's recommendations. Reactions were carried out in an ABI 7900 sequence detector (Perkin Elmer) and results were expressed as fold change calculated by the Ct method relative to the control sample. GAPDH and POLR2A were used as internal normalization controls.
Western Blot
Cells were lysed in RIPA buffer supplemented with protease inhibitors (Roche). Whole cell extracts were quantified using the BCA protein assay kit (Pierce) and were then separated on 7% -12% SDS-PAGE gels and transferred to polyvinylidene difluoride membranes. Membranes were blocked with 5% milk and probed with specific antibodies. Blots were then incubated with an HRP-linked second antibody and developed with chemiluminescence.
ELISA
For the quantitative determination of TGF-β2 protein levels secreted to the media, we used the Human TGF-β2 Quantikine ELISA kit (R&D systems) following manufacturer's specifications.
Supernatant from serum-starved cells was collected 72 hours after the start of the indicated treatments. 
Retroviral infections
293T Phoenix-Ampho cells were transfected using the calcium phosphate transfection method with the retroviral vectors pLNCX2, pLNCX2-ICER, pRetroSuper, pRetroSuper-shCREB1.
After 16 hours, medium was replaced and recombinant retrovirus was harvested for additional 24 hours. For infection, medium containing recombinant retrovirus was added to LN229 cells. Polybrene (Sigma) was added at a concentration of 8 μg/ml. Phoenix-Ampho cells were incubated in fresh medium for additional 8 hours; after this time, the LN229 cells were washed and the medium containing recombinant retrovirus from Phoenix-Ampho cells was added. This process of infection was repeated two more times every 8 hours. Two days later, antibiotic selection was added to the medium (puromycin (1μg/ml); neomycin (0.5 μg/ml); higromycin (100 μg/ml)).
Lentiviral infections
293T cells were transfected using the calcium phosphate transfection method with pMD2.G enveloping plasmid, psPAX.2 packaging plasmid and either pGIPZ or pGIPZ-shCREB1. After 16 hours, medium was replaced by neurosphere medium with 5mM Sodium Butyrate and recombinant lentivirus was harvested for additional 24 hours. For infection, medium containing recombinant lentivirus was added to previously dissociated neurospheres. Polybrene (Sigma) was added at a concentration of 8 μg/ml. Following 16 hours of incubation, the neurospheres were washed and incubated in fresh neurosphere medium.293T cells were incubated in fresh neurosphere medium containing Sodium Butyrate (5mM) for 24 hours and a second round of neurosphere infection was repeated as previously described.
Luciferase assays
Cells were transfected with different TGF-β2 promoter reporter constructs and pRL-TK Renilla luciferase plasmid (Promega) using Lipofectamine 2000. After a 16 hour incubation at 37°C, cells were treated with TGF-β for a further 32 hours. Luciferase counts were measured using a Sirius Luminometer (Berthold).
The firefly luciferase activity was normalized with renilla luciferase activity. Data are represented as relative activity (compared with basal promoter activity) and are expressed as the mean +/-s.d. of triplicates from a representative experiment.
Tissue microarrays and immunohistochemical staining
For tissue microarray generation, three 0.6 mm cores were taken from separate areas, and each one was arrayed into recipient blocks in a 1 mm-spaced grid.
Formalin-fixed, paraffin embedded tissue sections were deparaffinized and hydrated. Antigen retrieval was performed using pH 6 Citrate Antigen Retrieval Solution (DAKO). Peroxidase blocking was done with 3% H 2 O 2 at room temperature for 10 minutes. For TGF-β2, slides were incubated with a blocking solution (10% normal goat serum, 2% BSA) for 1 hour at room temperature. TGF-β2 antibody (Santa Cruz sc-90) was used at a 1:500 dilution, p-CREB1 (Cell Signaling 9198) was used at a 1:100 dilution, and p-SMAD2 (Cell Signaling 3108) was used at a 1:250 dilution. A human-specific anti-Nestin antibody was used at 1:200 dilution, to determine tumor area. As a detection system, EnVision FLEX+ was used (DAKO) following the manufacturer's instructions and developed with freshly prepared 0.05% 3′,3-diaminobenzidine tetrahydrochloride. Finally, the slides were counterstained with hematoxylin, dehydrated and Immunocomplexes were recovered with 30 μl of a protein A/G bead slurry. Immunoprecipitated material was washed three times with a low-salt buffer and once with a high-salt buffer. DNA complexes were de-crosslinked in 100 μl decrosslink buffer (1% SDS and 100 mM NaHCO 3 ) at 65 C for 3 hours, and DNA was then eluted in 100 μl of water using a PCR purification kit (Qiagen). DNA (2 μl) was used for each qRT-PCR reaction with SYBR green (Roche).
Antibodies against SMAD2/3 (Upstate), ChIPAb+™ Phospho-CREB1 (Ser133) (Millipore) and rabbit IgG (Upstate) were used for ChIP. The proximal TGF-β2 promoter primer set utilized spans -84 to -18 relative to the transcriptional start site. 
